| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1044 |
| Trial ID | ChiCTR-OIC-17013523 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I study of autologous anti-CD22 (human derived) chimeric antigen receptor T cells treating refractory and relapsed B acute lymphoblastic leukemia |
| Year | 2017 |
| Country | China |
| Company sponsor | Beijing Boren Hospital |
| Cohort 1 | |||||||||
|
|||||||||